CuriosityStream CURI Q1 2026 Earnings Transcript

CuriosityStream reported Q1 2026 revenue of $15.2 million, up slightly from $15.1 million, with licensing revenue rising 11% to $6 million and adjusted EBITDA positive for the fifth straight quarter at $0.9 million. Adjusted free cash flow was $1.3 million for a ninth consecutive positive quarter, gross margin improved to 56% from 53%, and the company raised its quarterly dividend 70% to $0.085 per share while buying back $300,000 of stock. Management guided to $75 million-$80 million in 2026 revenue and $16 million-$20 million in adjusted EBITDA, citing momentum in AI licensing and a planned $1.9 million German business buyout expected to be accretive.

Analysis

CURI’s quarter reads less like a demand slowdown and more like a deliberate re-pricing of the business toward a higher-multiple revenue mix. The key second-order effect is that management is explicitly sacrificing near-term recognition to widen partner breadth and deepen data rights, which should improve lifetime value if repeat licensing becomes the norm; that matters because the market usually underwrites these micro-caps on visible quarterly revenue, not on corpus optionality. If they can convert pilots into multi-quarter framework contracts, the operating model can re-rate quickly because marginal delivery costs should stay low while pricing power rises for scarce, rights-cleared, multimodal assets.

The more interesting setup is the cash-return story. Raising the dividend while still buying back stock signals confidence, but it also creates a floor for the equity so long as A) licensing cash flows keep outrunning distributions and B) SBC doesn’t continue to swamp GAAP earnings optics. That combination can work in the near term, but it is fragile: if licensing timing slips by even one quarter, investors may start to view the dividend step-up as a signaling mistake rather than a capital-allocation flex.

The biggest contrarian point is that the AI narrative may be less about total addressable market and more about procurement bottlenecks inside large model companies. The winners are likely the few vendors with both ownership clarity and production-grade multimodal depth; the losers are generic data brokers and smaller libraries that cannot package rights cleanly. Near-term catalysts are a larger contract announcement, evidence the German consolidation is accretive, and confirmation that first-half guidance is a real run-rate rather than a backlog pull-forward; the main risk is that Q2 and Q3 show lumpy recognition again and the stock trades back to a yield trap despite improving underlying economics.

Key Decisions for Investors

• Long CURI common on any post-earnings consolidation, with a 3-6 month horizon; thesis is that the market is underpricing framework/pilot conversion and will re-rate on one or two visible enterprise AI wins. Risk/reward is attractive if cash flow remains positive, but size modestly because revenue recognition remains lumpy.
• Buy CURI Jan-2027 call spreads (e.g., 10/15 strikes) if options liquidity allows; this expresses the view that 2026 guidance proves conservative and that the market will eventually pay for recurring licensing mix. The spread limits decay if contract timing slips.
• Pair trade: long CURI / short a basket of lower-quality ad-supported media or generic content aggregators over the next 2-4 quarters. The idea is that rights-cleared, multimodal data gets premium pricing while commoditized libraries face compression.
• Do not chase the stock solely for the >11% dividend yield; wait for confirmation that operating cash flow continues to fully cover the new payout for 1-2 quarters. If coverage weakens, the yield becomes a value trap and downside can accelerate quickly.
• Add only after evidence of accretive German consolidation and at least one disclosed large AI renewal or expansion; those are the catalysts most likely to force a multiple expansion rather than just a yield/FCF rerating.